公开(公告)号：US20240360417A1

公开(公告)日：2024-10-31

申请号：US18631774

申请日：2024-04-10

Applicant: Cell&Brain Co., Ltd

Inventor： Hae Young SUH ,  Sung Soo KIM ,  Da Young CHANG ,  Jin Hwa JUNG ,  Young Don LEE ,  Woo Sup HWANG ,  Jin Sung PARK ,  Su Jung LEE

IPC: C12N5/0775 ,  A61K31/4188 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K33/243 ,  A61K33/244 ,  A61K35/12 ,  A61K35/28 ,  A61K45/06

CPC classification number: C12N5/0665 ,  A61K31/4188 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/513 ,  A61K31/675 ,  A61K31/704 ,  A61K33/243 ,  A61K33/244 ,  A61K35/12 ,  A61K35/28 ,  A61K45/06 ,  C12N5/0663 ,  C12N2501/73 ,  C12N2510/00 ,  C12N2523/00

Abstract: The present disclosure relates to a method for preparing cells for cancer treatment and a kit for cancer treatment comprising cells prepared by the method. The preparation method of the present disclosure can provide F cells, which, in spite of having no difference in the proliferative capacity compared with mesenchymal stem cells expressing cytosine deaminase that are harvested and used immediately after the culture, exhibit a very excellent tumor suppressive effect through the treatment together with 5-FC and induce a remarkable synergistic effect exceeding an effect from combinative treatment with an existing anticancer drug in cases of a combinative treatment with another anticancer drug. Therefore, the present disclosure can be utilized for a kit for cancer treatment comprising such F cells, and thus can be favorably used to maximize the effect of existing cancer treatments.

公开(公告)号：US20240336894A1

公开(公告)日：2024-10-10

申请号：US18402999

申请日：2024-01-03

Applicant: Affiliated Hospital of Jiangsu University

Inventor： Xuefeng Wang ,  Yongbin Ma

IPC: C12N5/0786

CPC classification number: C12N5/0645 ,  C12N2500/02 ,  C12N2500/05 ,  C12N2500/30 ,  C12N2500/84 ,  C12N2509/00 ,  C12N2523/00 ,  C12N2527/00 ,  C12N2529/00

Abstract: A simple and efficient method for separating migrasomes from macrophages is provided. The method separates migrasomes having a diameter range of 0.5 micrometers (μm) to 3 μm by intercepting through a filter and eluting through reverse filtration successfully. The separated migrasome has a vesicle-liked structure and wrinkles on its surface, and the separated migrasome has a diameter over 500 nanometers (nm). The separated migrasomes express their characteristic proteins PIGK, EOGT, and TSPAN4, but do not express specific markers TSG101 and ALIX of EVs, indicating that the separated migrasomes are a unique type of vesicles distinct from extracellular vesicles (EVs). The integrity of ribonucleic acids (RNA) carried by the migrasomes is not affected. The method for separating migrasomes from macrophages has the characteristics of simplicity, high efficiency, good controllability, good repeatability, and low cost, and large special equipment is not needed.

公开(公告)号：US20240279354A1

公开(公告)日：2024-08-22

申请号：US18626607

申请日：2024-04-04

Applicant: AMUNIX PHARMACEUTICALS, INC.

Inventor： Volker SCHELLENBERGER ,  Fan YANG ,  Desiree THAYER ,  Bee-Cheng SIM ,  Chia-Wei WANG

IPC: C07K16/30 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/00 ,  C07K16/28 ,  C12N5/09

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/00 ,  C07K16/2809 ,  C12N5/0693 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01 ,  C07K2319/035 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  C12N2523/00

Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

公开(公告)号：US20240271101A1

公开(公告)日：2024-08-15

申请号：US18517468

申请日：2023-11-22

Applicant: Hoffmann-La Roche Inc.

Inventor： Ingo Gorr ,  Oliver Popp ,  Alina Schneider

IPC: C12N5/071 ,  A61K47/68 ,  C12N15/85

CPC classification number: C12N5/0682 ,  A61K47/6845 ,  A61K47/6849 ,  C12N15/85 ,  C12N2015/8518 ,  C12N2500/60 ,  C12N2523/00

Abstract: Herein is reported a method for producing an immunoconjugate with reduced product- and process-related impurities by culturing mammalian cells that contain one or more nucleic acids encoding the immunoconjugate of interest in a cell culture medium, wherein the one or more nucleic acids are expressed under the conditions of cell culture comprising the steps of:



culturing the mammalian cells in a cell culture medium at a first temperature and at a first pH;
reducing the first temperature of the cell culture medium to a second temperature; and increasing the first pH of the cell culture medium to a second pH;
recovering the immunoconjugate from the cells or the cell culture medium,

and thereby producing the immunoconjugate.

公开(公告)号：US20240247234A1

公开(公告)日：2024-07-25

申请号：US18401238

申请日：2023-12-29

Applicant: WUHAN OPTICS VALLEY ZHONGYUAN PHARMACEUTICAL CO., LTD.

Inventor： Yu ZHANG ,  Qi QI ,  Yun ZHANG ,  Ruizhen HOU ,  Wenjie WU ,  Wangyi ZHOU ,  Lei WANG

IPC: C12N5/0775 ,  A61K35/28 ,  A61P1/16 ,  A61P11/00 ,  A61P31/14

CPC classification number: C12N5/0665 ,  A61K35/28 ,  A61P1/16 ,  A61P11/00 ,  A61P31/14 ,  C12N2523/00

Abstract: TA preparation method for off-the-shelf human umbilical cord-derived mesenchymal stem cells includes culturing an isolated umbilical cord tissue blocks to obtain P0 cells; carrying out passage on the P0 cells twice to obtain P2 cells, and cryopreserving the P2 cells; the cryopreserved P2 cells are subjected to thawing and passage twice to obtain P4 cells, and the P4 cells are cryopreserved; the cryopreserved P4 cells are subjected to thawing and passage once to obtain P5 cells, and the P5 cells are sequentially digested, washed and resuspended to obtain the human umbilical cord-derived mesenchymal stem cells. The present invention also adopts cryopreservation method to develop a cryopreservation preparation of human umbilical cord-derived mesenchymal stem cells. The cryopreservation preparation is convenient for storage and can be directly administered intravenously after thawing without changing the liquid, avoiding possible contamination risk during dispensing, and is more conducive to clinical use.

公开(公告)号：US20240200005A1

公开(公告)日：2024-06-20

申请号：US18555347

申请日：2022-04-14

Applicant: SCREENSYS GMBH

Inventor： Jialan CAO ,  Alexander GROSS ,  Johann Michael KÖHLER ,  Patrick SCHAUB ,  Klaus PALME ,  Oleksandr DOVZHENKO

IPC: C12M3/06 ,  C12M1/00 ,  C12M1/34 ,  C12N5/04 ,  G01N15/1434 ,  G01N15/149 ,  G01N33/00

CPC classification number: C12M23/16 ,  C12M41/46 ,  C12M47/04 ,  C12N5/04 ,  G01N15/1434 ,  G01N15/149 ,  G01N33/0098 ,  C12N2523/00 ,  C12N2529/10

Abstract: The present invention relates to a method for developing and/or reprogramming plant cellular objects comprising the steps: providing a reservoir containing a medium with plant cellular objects: providing a first set of compartments of sample fluid embedded in carrier fluid in a microfluidic conduit, wherein the carrier fluid is immiscible with the medium, wherein the first set's compartments of sample fluid each comprise medium and at least one plant cellular object: providing one or more first state triggers to the plant cellular objects in the microfluidic conduit for inducing a first state in the plant cellular objects of the first set of compartments: incubating the plant cellular objects of the first set of compartments in the microfluidic conduit for a time span sufficient for the plant cellular objects to transfer to the first state: selecting one or more first selection parameters indicative of the first state: identifying, within the first set of compartments in the microfluidic conduit, compartments according to the one or more first selection parameters and optionally assigning the compartments with respective state identifiers.

公开(公告)号：US20240173364A1

公开(公告)日：2024-05-30

申请号：US18521383

申请日：2023-11-28

Applicant: The Penn State Research Foundation ,  The University of Adelaide

Inventor： Peter Zilm ,  Lisa Jamieson ,  Laura Weyrich

IPC: A61K35/742 ,  C12M1/12 ,  C12N1/20 ,  C12R1/07 ,  C12R1/21

CPC classification number: A61K35/742 ,  C12M23/06 ,  C12M25/14 ,  C12N1/205 ,  C12N2500/14 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2500/46 ,  C12N2500/74 ,  C12N2500/84 ,  C12N2501/998 ,  C12N2513/00 ,  C12N2523/00 ,  C12N2533/18 ,  C12R2001/07 ,  C12R2001/21

Abstract: Provided herein are methods, compositions, and systems for treating dental caries and a periodontal disease based on microbiome modulation through oral microbiome transplant (OMT). The original oral microbial composition was obtained from the dental plaque of healthy donors, and then modulated by growing a biofilm in vitro in a growth medium. The modulated oral microbial composition has a different microbial diversity than the original oral microbial composition. In the modulated oral microbial compositions, the abundance of some bacterial species changes, some new bacterial species are present, and some original bacterial species are no longer present. The modulated oral microbial composition is transplanted to the recipient's oral cavities through OMT to treat dental caries or a periodontal disease.

公开(公告)号：US20240158465A1

公开(公告)日：2024-05-16

申请号：US18517066

申请日：2023-11-22

Applicant: GEORGE MASON UNIVERSITY

Inventor： Caroline Dieckmann Hoemann ,  Julia Alexa Leonard ,  Virginia A. Espina ,  David Kepplinger

IPC: C07K14/705 ,  C12N5/0787 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K14/7056 ,  C12N5/0642 ,  G01N33/5047 ,  G01N33/6893 ,  C12N2501/052 ,  C12N2501/90 ,  C12N2501/999 ,  C12N2523/00 ,  G01N2333/8125

Abstract: In an embodiment, present invention relates to a method of generating, ex vivo production of soluble Lox-1 (sLox-1), comprising: introducing a sample containing blood into a device; adding a coagulation enhancing material in the sample to form a cultured blood clot; incubating the cultured blood clot in the device at a temperature greater than 25° C. and less than 45° C. for at least 2 hours to allow production of Lox-1 from neutrophils of blood and to shed the sLox-1 outside the cultured blood clot; and collecting sLox-1 shedded in the device, wherein the method is configured to shed sLox-1 more than fresh blood.

公开(公告)号：US20240150723A1

公开(公告)日：2024-05-09

申请号：US18283614

申请日：2022-03-22

Applicant: Biogen MA Inc.

Inventor： Taylor Forte ,  Christoper Kwiatkowski ,  Greg Evangelist ,  Taylor Roland ,  Krishnakumar Malu

IPC: C12N5/071

CPC classification number: C12N5/0682 ,  C12N2500/24 ,  C12N2500/30 ,  C12N2523/00

Abstract: In some instances, the application provides methods of culturing host cells comprising a gene encoding a recombinant N protein in a cell culture medium, wherein the cell culture medium comprises: (i) iron at a concentration of less than 1200 μM; and (ii) citrate at a concentration of less than 2400 μM. In some instances, the methods comprise culturing host cells expressing a recombinant protein in a cell culture medium at a first temperature; and decreasing the first temperature to a second temperature. In some instances, the methods comprise purifying the recombinant protein by a carbon depth filtration.

公开(公告)号：US11926651B2

公开(公告)日：2024-03-12

申请号：US16335022

申请日：2017-09-20

Applicant: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.

Inventor： Monika Hochradl ,  Frank Stolz ,  Angela Neubauer ,  Rainer Henning ,  Elijahu Babaev

IPC: C07K14/415 ,  A61K39/00 ,  A61K39/36 ,  A61P37/08 ,  C07K14/005 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66

CPC classification number: C07K14/415 ,  A61K39/36 ,  A61P37/08 ,  C07K14/005 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  A61K2039/575 ,  A61K2039/6075 ,  C07K2319/00 ,  C07K2319/21 ,  C12N2511/00 ,  C12N2523/00 ,  C12N2730/10122 ,  C12N2730/10134

Abstract: The present invention relates to a polypeptide construct comprising at least two fragments of an allergen from the Amb a 1 family of allergens from Ambrosia atermisiifolia or variants of said at least two fragments, wherein each of the at least two fragments consist of 20 to 50 amino acid residues and wherein at least one fragment is derived from amino acid residues 1 to 50 of the mature allergen and at least one fragment is derived from amino acid residues 240 and ending at the C-terminal end of the mature allergen.